West Corporation Announces Loan Repricing and Amendment to Credit Agreement
Dec 19, 2016 21:15 pm UTC| Business
OMAHA, Neb., Dec. 19, 2016 -- West Corporation, a global provider of communication and network infrastructure services, announced today that it has finalized and closed on an amendment to the credit agreement governing...
The Ensign Group, Inc. Increases Quarterly Dividend by 6.3% to $0.0425 Per Share
Dec 19, 2016 21:15 pm UTC| Business
MISSION VIEJO, Calif., Dec. 19, 2016 -- The Ensign Group, Inc. (NASDAQ:ENSG), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, hospice care and assisted living companies, today...
Nabriva Announces Closing of Rights Offering and Underwritten Offering
Dec 19, 2016 21:13 pm UTC| Business
VIENNA, Austria and KING OF PRUSSIA, Pa., Dec. 19, 2016 -- (NASDAQ:NBRV) – Nabriva Therapeutics AG announced today the closing of its previously announced rights offering for up to 588,127 common shares, including...
Integra LifeSciences to Present at the 35th Annual J.P. Morgan Healthcare Conference in January 2017
Dec 19, 2016 21:05 pm UTC| Business
PLAINSBORO, N.J., Dec. 19, 2016 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it will present at the following conference in January: At 2:30PM PT on Wednesday, January 11, 2017, Mr....
James River Group Holdings, Ltd. Announces Appointment of Chief Financial Officer
Dec 19, 2016 21:05 pm UTC| Business
PEMBROKE, Bermuda, Dec. 19, 2016 -- James River Group Holdings, Ltd. (NASDAQ:JRVR) today announced that Sarah C. Doran has been appointed Chief Financial Officer of the Group’s holding companies. Ms. Doran will have...
Sucampo Announces Proposed Convertible Senior Note Offering
Dec 19, 2016 21:01 pm UTC| Business
ROCKVILLE, Md., Dec. 19, 2016 -- Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), a global biopharmaceutical company, today announced its intention to offer, subject to market and other conditions, $225.0 million principal...
Dec 19, 2016 21:01 pm UTC| Business
THE WOODLANDS, Texas, Dec. 19, 2016 -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has requested a meeting to discuss Phase 3 requirements for the development of Proellex® (telapristone acetate) for the...